Benjamin Stone
Vermögen: 275 502 $ am 31.05.2026
Vermögen: 275 502 $ am 31.05.2026
Benjamin Stone is the founder of IconOVir Bio, Inc.,76Bio, Inc. Mr. Stone currently holds the position of Chief Business Officer at AnaptysBio, Inc. since 2022.
Mr. Stone also serves as Chief Business Officer at First Tracks Biotherapeutics, Inc. Mr. Stone completed undergraduate education at the University of Pennsylvania and The Wharton School of the University of Pennsylvania.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,05 % | 12.05.2026 | 17.262 ( 0,05 % ) | 275 502 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ANAPTYSBIO, INC. | Corporate Officer/Principal | 01.01.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
IconOVir Bio, Inc.
IconOVir Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops oncolytic virus therapy to improve the treatment of patients with cancer | Gründer | - |
76bio, Inc.
76bio, Inc. Pharmaceuticals: MajorHealth Technology Develops transformational therapies for patients with life-threatening disease | Gründer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
AnaptysBio, Inc.
AnaptysBio, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IconOVir Bio, Inc.
IconOVir Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops oncolytic virus therapy to improve the treatment of patients with cancer | Health Technology |
76bio, Inc.
76bio, Inc. Pharmaceuticals: MajorHealth Technology Develops transformational therapies for patients with life-threatening disease | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen